Solid Cancers Clinical Trial
Official title:
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer
This study is for subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes). The overall goal of this study is to identify plant-derived phytochemicals that can safely reduce systemic inflammation (inflammation throughout the entire body) in subjects with advanced cancer.
This study will look at oligomeric procyanidin complex (OPC) and vitamin D3. OPC is the major part of Grape Seed Extract (GSE). Researchers are in looking at the combination of GSE and vitamin D in subjects with solid cancers (gastrointestinal, lung, breast, prostate, lymphoma or cancer of the lymph nodes). Researchers will examine the safety of the GSE and vitamin D when GSE is given at different doses. Researchers will also look at the effects of GSE and vitamin D on your quality of life and your body. In particular, they will look at differences in biomarkers in your blood and urine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01301716 -
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT00968981 -
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
|
Phase 1 | |
| Completed |
NCT00747734 -
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01226277 -
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
| Completed |
NCT00876109 -
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
|
Phase 1 | |
| Completed |
NCT01209143 -
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
|
Phase 1 | |
| Completed |
NCT00996892 -
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03514368 -
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
|
N/A | |
| Completed |
NCT00909740 -
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00096941 -
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
|
Phase 2 | |
| Completed |
NCT01546519 -
A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function
|
Phase 1 | |
| Completed |
NCT01090960 -
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01296555 -
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
|
Phase 1 | |
| Completed |
NCT01139723 -
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00977067 -
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
|
Phase 1 | |
| Completed |
NCT01332604 -
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00927589 -
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
|
Phase 1 | |
| Recruiting |
NCT05228106 -
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
|
||
| Completed |
NCT02323191 -
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01075464 -
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 |